Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST)
Kacper Wasielewski1, B. Wasag1,2, A. Wozniak3, J. Pikiel4, A. Kowalik5, C. Osuch6, E. Bylina7, J. A. Siedlecki8, P. Rutkowski7, J. Limon1,2
1Department of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland 2Laboratory of Clinical Genetics, University Clinical Centre, Gdansk, Poland 3Laboratory of Experimental Oncology, Department of Oncology, KU Leuven and Department of General Medical Oncology, University Hospitals in Leuven, Leuven, Belgium 4Regional Oncology Centre, Gdansk, Poland 5Department of Molecular Diagnostics, Holycross Cancer Centre, Kielce, Poland 6Department of General Surgery, Medical Faculty, Jagiellonian University, Krakow, Poland 7Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland 8Department of Translational and Molecular Oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
Received November 2016
Accepted January 2017
Crossref Cited-by Linking
Chen Yan, Dong Xiuhua, Wang QiuJu, Liu ZhiXi, Dong XinWei, Shi Sanjun, Xiao HongTao: Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia. Front. Pharmacol.2020, 11. <https://doi.org/10.3389/fphar.2020.569843>
